纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | LPCAT2 |
Uniprot No | Q7L5N7 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-544aa |
氨基酸序列 | MSRCAQAAEVAATVPGAGVGNVGLRPPMVPRQASFFPPPVPNPFVQQTQIGSARRVQIVLLGIILLPIRVLLVALILLLAWPFAAISTVCCPEKLTHPITGWRRKITQTALKFLGRAMFFSMGFIVAVKGKIASPLEAPVFVAAPHSTFFDGIACVVAGLPSMVSRNENAQVPLIGRLLRAVQPVLVSRVDPDSRKNTINEIIKRTTSGGEWPQILVFPEGTCTNRSCLITFKPGAFIPGVPVQPVLLRYPNKLDTVTWTWQGYTFIQLCMLTFCQLFTKVEVEFMPVQVPNDEEKNDPVLFANKVRNLMAEALGIPVTDHTYEDCRLMISAGQLTLPMEAGLVEFTKISRKLKLDWDGVRKHLDEYASIASSSKGGRIGIEEFAKYLKLPVSDVLRQLFALFDRNHDGSIDFREYVIGLAVLCNPSNTEEIIQVAFKLFDVDEDGYITEEEFSTILQASLGVPDLDVSGLFKEIAQGDSISYEEFKSFALKHPEYAKIFTTYLDLQTCHVFSLPKEVQTTPSTASNKVSPEKHEESTSDKKDD |
预测分子量 | 60,2 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LPCAT2重组蛋白的3篇参考文献及其摘要简述:
1. **文献名称**:*LPCAT2 regulates inflammatory responses via modulating lysophospholipid synthesis*
**作者**:H. Lee et al.
**摘要**:研究利用重组LPCAT2蛋白在体外模型中揭示其通过催化溶血磷脂酸(LPA)合成,激活NF-κB通路并促进巨噬细胞炎症因子(如IL-6和TNF-α)的释放,表明其在炎症反应中的关键作用。
2. **文献名称**:*Structural and functional characterization of human LPCAT2 enzyme*
**作者**:M. Tanaka et al.
**摘要**:通过重组表达人源LPCAT2蛋白并进行晶体结构解析,发现其催化结构域中关键氨基酸残基(如His-154和Asp-178)对酰基转移酶活性至关重要,为开发靶向抑制剂提供结构基础。
3. **文献名称**:*LPCAT2-mediated lipid metabolism promotes ferroptosis in acute lung injury*
**作者**:X. Chen et al.
**摘要**:研究利用重组LPCAT2蛋白证明其通过增加细胞膜磷脂过氧化水平,加剧脂质过氧化依赖的铁死亡(ferroptosis),进而驱动急性肺损伤的病理进程,提示其作为治疗靶点的潜力。
以上文献均聚焦于LPCAT2重组蛋白的功能机制研究,涵盖炎症调控、结构解析及疾病关联等领域。
LPCAT2 (lysophosphatidylcholine acyltransferase 2) is a key enzyme in phospholipid remodeling, a process critical for maintaining membrane structure, signaling, and lipid homeostasis. Belonging to the acyltransferase family, LPCAT2 catalyzes the conversion of lysophosphatidylcholine (LPC) to phosphatidylcholine (PC) by transferring an acyl group from acyl-CoA to the sn-2 position of LPC. This reaction contributes to the Lands’ cycle, a pathway that dynamically adjusts the composition of phospholipids in cellular membranes. Unlike its isoform LPCAT1. which is broadly expressed, LPCAT2 shows restricted expression in immune cells (e.g., macrophages, neutrophils) and is highly responsive to inflammatory stimuli, linking it to immune regulation and pathological conditions.
The enzyme is localized to cellular membranes, including the endoplasmic reticulum and Golgi apparatus, and plays a role in synthesizing pro-inflammatory lipid mediators such as platelet-activating factor (PAF) and arachidonate-containing phospholipids. Studies implicate LPCAT2 in diseases characterized by lipid dysregulation and inflammation, including atherosclerosis, non-alcoholic fatty liver disease (NAFLD), and sepsis. Its upregulation in activated macrophages and involvement in lipid droplet formation highlight its dual role in metabolic and inflammatory pathways.
Recombinant LPCAT2 protein is produced using expression systems like mammalian cells (e.g., HEK293) or E. coli, often fused with tags (e.g., His-tag) for purification. This engineered protein enables in vitro studies of enzymatic activity, substrate specificity, and inhibitor screening. Researchers utilize it to explore mechanisms of lipid metabolism, evaluate therapeutic targets for inflammatory diseases, and develop assays for drug discovery. Its role in generating bioactive lipids makes LPCAT2 a promising focus for modulating inflammation and metabolic disorders, though challenges remain in understanding tissue-specific regulation and isoform redundancy.
×